Researchers have found a treatment that can eradicate advanced stage mesothelioma tumors within a few days. The research is being done at Rice University and Baylor College of Medicine. The treatment utilizes implants known as “drug factories” and a checkpoint inhibitor drug. Mesothelioma is a tough to treat cancer of[…]
Latest Immunotherapy Treatments
Keytruda as a Second Line Treatment for Mesothelioma
A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]
SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]
Galinpepimut-S Cancer Vaccine in Combination with Opdivo
Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy[…]
Targeted Therapy is Showing Promising Results for Mesothelioma
Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease[…]
Vudalimab for the Treatment of Mesothelioma
The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma
A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]
A Cancer Vaccine Could Potentially Help Mesothelioma Patients
Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future. The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually[…]
OT-101 Useful for COVID-19 and Cancers Like Mesothelioma
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]
Tremelimumab and Durvalumab Combination Can Improve Mesothelioma Survival
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the[…]
Skip to content